La UEG Week tendrá lugar en Barcelona del 17 al 20 de octubre de 2026. A continuación puede consultar la producción de los miembros de GETECCU en esta edición:

Ana Gutiérrez	MP0012, domingo 18. 09:06-09:12. Hall 7-Poster Stage 2 EFFECTIVENESS AND SAFETY OF MIRIKIZUMAB IN ULCERATIVE COLITIS: REAL-ORLD EVIDENCE FROMTHE MIRICURE STUDY OF GETECCU
María José Casanova	MP0025, domingo 18. 09:24-09:30. Hall 7-Poster Stage 3 PREVALENCE, CLINICAL CHARACTERISATION AND THERAPEUTIC OUTCOMES OF NON-FISTULISING PERIANAL LESIONS IN CROHN’S DISEASE (ULCERS-CD): RESULTS FROM THE ENEIDA REGISTRY OF GETECCU
Francisco López Romero-Salazar	PP0916, domingo 18. 09:00-09:00, Hall 7-Poster area CHARACTERISTICS OF SUBACUTE AND CHRONIC INTESTINAL FAILURE SECONDARY TO INFLAMMATORY BOWEL DISEASE IN A SPANISH COHORT: A NATIONAL MULTICENTER STUDY FROM YOUNG GETECCU GROUP.
Diego Casas Deza	PP0002, domingo 18. 09:00-09:00, Hall 7-Poster area IMPACT OF CMV SUPERINFECTION ON THE CLINICAL COURSE OF PATIENTS WITH MODERATE-TO-SEVERE IMMUNE-MEDIATED COLITIS: RESULTS FROM THE REGIC STUDY PROMOTED BY GETECCU PP0009, domingo 18. 09:00-09:00, Hall 7-Poster area PREDICTORS OF STEROID FAILURE AND OUTCOMES OF RESCUE THERAPY IN SEVERE IMMUNE CHECKPOINT INHIBITORS-INDUCED COLITIS: A MULTICENTER STUDY FROM GETECCU OP221, martes 20. 09:00-09:10. Room D3 RISK FACTORS FOR RECURRENCE AFTER A FIRST EPISODE OF IMMUNE-MEDIATED COLITIS AND THE ROLE OF CONCOMITANT BIOLOGIC THERAPY: THE GETECCU-PROMOTED REGIC STUDY PP1177, domingo 18. 09:00-09:00, Hall 7 Poster area EFFECTIVENESS AND SAFETY OF COMBINATION TARGETED THERAPY IN INFLAMMATORY BOWEL DISEASE: THE COMBEII STUDY FROM THE ENEIDA REGISTRY OP291, martes 20. 14:30-14.40, Room B3 IMPACT OF THE ORDER OF THE FIRST TWO BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE: THE SECUTEM STUDY FROM THE ENEIDA REGISTRY MP1057, martes 20. 15:24-15:30. Hall 7 – Poster Stage 2 EFFECTIVENESS OF ANTI-TNF THERAPY AFTER A DIFFERENT MECHANISM OF ACTION: REAL-WORLD EVIDENCE FROM THE ENEIDA REGISTRY
Alejandro Hernández-Camba	PP1432, domingo 18. 09:00-09:00, Hall 7-Poster area CONCOMITANT INFLAMMATORY BOWEL DISEASE AND EOSINOPHILIC ESOPHAGITIS (CECIBDEE): A MULTICENTRE GETECCU STUDY
María Chaparro	MP0431, lunes 19. 10:06-10:12. Hall 7- Poster Stage 2 USTEKINUMAB EXPOSURE DURING PREGNANCY AND RISK OF SMALL FOR GESTATIONAL AGE IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE DUMBO REGISTRY OF GETECCU
Marta Velasco Rodríguez-Belvís	MP0436, lunes 19. 10:36-10:42. Hall 7- Poster Stage 2 SAFETY OF INFANT VACCINATION AFTER MATERNAL BIOLOGIC EXPOSURE  DURING PREGNANCY OR BREASTFEEDING IN INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE MULTICENTRE COHORT STUDY OF THE DUMBO REGISTRY OF GETECCU
Arnau Artero Cruañas	MP0439, lunes 19. 10:54-11:00. Hall 7- Poster Stage 2 QUALITY OF HUMAN PAPILLOMAVIRUS SCREENING IN WOMEN WITH INFLAMMATORY BOWEL DISEASE (EII-VIP STUDY OF GETECCU)
Esteban Fuentes Valenzuela	MP0587, lunes 19. 13:42-13:48. Hall 7 – Poster Stage 3 SAFETY AND EFFECTIVENESS OF ADVANCED THERAPIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND COMPENSATED CIRRHOSIS. HEP-IBD STUDY. A STUDY FROM THE YOUNG GROUP OF GETECCU
Óscar Moralejo Lozano	MP0759, lunes 19. 16:00-16:06. Hall 7 – Poster Stage 7 DRUG-INDUCED AUTOIMMUNE-LIKE HEPATITIS INDUCED BY ANTI-TNF IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE CASE-CONTROL STUDY. THE DIALHATI STUDY FROM GETECCU YOUNG GROUP
Santiago García-López	MP0974, martes 20. 13:30-13:36. Hall 7 – Poster Stage 1 DISTINCT MICROBIOLOGICAL PROFILE OF INTRA-ABDOMINAL ABSCESSES IN CROHN’S DISEASE: A MULTICENTER COHORTS STUDY FROM GETECCU MP1047, martes 20. 15:24-15:30. Hall 7 – Poster Stage 1 IMPORTANCE OF PAIN AS A CLINICAL MANIFESTATION IN THE COURSE AND SEVERITY OF SEVERE IMMUNE-MEDIATED COLITIS: DATA FROM THE GETECCU REGIC STUDY
Iago Rodríguez-Lago	PP1234, domingo 18. 09:00-09:00, Hall 7 Poster area LONGITUDINAL TRAJECTORIES OF CLINICAL RESPONSE TO FILGOTINIB IN ULCERATIVE COLITIS: ANALYSIS FROM THE ENEIDA REGISTRY
Cristina Rubín de Célix	MP1050, martes 20. 14:42-14:48. Hall 7 – Poster Stage 2 COMPARATIVE STUDY ON THE EFFECTIVENESS, DURABILITY, AND SAFETY OF UPADACITINIB VERSUS RISANKIZUMAB AFTER ANTI-TNF FAILURE IN CROHN’S DISEASE: THE U-PARIS STUDY OF ENEIDA